Nuvalent, Inc.

Nuvalent, Inc. is a clinical-stage biopharmaceutical company dedicated to developing precisely targeted therapies for cancer patients. The company's core mission is to overcome the limitations of existing treatments for clinically validated kinase targets by leveraging deep expertise in chemistry and structure-based drug design. This approach aims to create innovative small molecules that can address drug resistance, minimize adverse events, penetrate the brain to treat metastases, and ultimately drive more durable patient responses. Nuvalent's headquarters are located in Cambridge, Massachusetts, United States, specifically at One Broadway, 14th Floor.

The company is advancing a robust pipeline of investigational drug candidates, primarily focusing on non-small cell lung cancer (NSCLC) driven by ROS1-positive, ALK-positive, and HER2-altered mutations. Its lead programs include zidesamtinib (NVL-520), a brain-penetrant ROS1-selective inhibitor, and neladalkib (NVL-655), an ALK-selective inhibitor. These therapies are designed to solve the dual challenges of kinase resistance and selectivity, aiming to provide durable responses for patients by targeting specific genetic mutations and overcoming issues like resistance to prior therapies, central nervous system (CNS) progression, and off-target toxicities.

Nuvalent has seen significant recent developments, including the FDA's acceptance of the New Drug Application (NDA) for zidesamtinib for ROS1-positive NSCLC, with a Prescription Drug User Fee Act (PDUFA) target action date of September 18, 2026, and an anticipated commercial launch in the United States in 2026. An NDA submission for neladalkib in ALK-positive NSCLC is also planned for the first half of 2026. James R. Porter, PhD, serves as the Chief Executive Officer. The company maintains a strong financial position, reporting approximately $1.37 billion in cash, cash equivalents, and marketable securities as of December 31, 2025, which is projected to fund operations through 2029.